Status:
COMPLETED
Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Depression
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
This study will determine the effectiveness of adding S-adenosyl methionine to antidepressant drug treatment in reducing depressive symptoms in depressed people who have not responded to antidepressan...
Detailed Description
Some people with depression do not respond well to antidepressant treatment. S-adenosyl methionine (SAMe) is a naturally occurring compound that may have antidepressant effects. SAMe may also enhance ...
Eligibility Criteria
Inclusion
- Major depressive disorder
- Use of an SSRI for at least 6 weeks prior to study entry with partial or no response
Exclusion
- History of psychosis
- Allergy to SAMe
- Alcohol or drug abuse in the past 3 months prior to study entry
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT00093847
Start Date
May 1 2004
End Date
February 1 2009
Last Update
October 13 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114